close
close
Skip to main content
Lasque Tiarc

Adult vaccination programs provide socio-economic benefits of up to 1

Vaseline 2 months ago

Business Wire India

    shows that adult immunization programs return up to 19 times their initial investment when the full spectrum of benefits are appreciated

  • The findings highlight the opportunity to alleviate pressure on healthcare systems by adopting a prevention mindset that includes adult immunization programs
  • The report comes ahead of World Immunization Week and reveals substantial differences between countries in the availability of evidence to rate vaccination in adults

A new report published today shows that adult vaccination programs could recoup up to 19 times their initial investment if the full spectrum of economic and social benefits is appreciated. The 19x return corresponds to a maximum of USD 4,637 in net financial benefits for society per individual complete vaccination course.

This press release contains multimedia. View the full press release here: https://www.businesswire.com/news/home/20240417519822/en/

Learn more about the economic benefits of investing in adult immunization programs in a new study from the Office of Health Economics (OHE).  Graphic: OHE

Learn more about the economic benefits of investing in adult immunization programs in a new study from the Office of Health Economics (OHE). Graphic: OHE

The study, a first-of-its-kind analysis of adult immunization programs by the Office of Health Economics (OHE) and commissioned by IFPMA (1), looked at four adult vaccines in ten countries where they are available to impact the broader economic determine the situation. and social impact.

The study focuses on vaccines that protect against influenza (flu), pneumococcal disease, respiratory syncytial virus (RSV) and herpes zoster (shingles) and looks at the implementation of vaccine programs in countries that have a range of healthcare systems, demographics and vaccination schedules – Australia , Brazil, France, Germany, Italy, Japan, Poland, South Africa, Thailand and the United States.

The report concludes that vaccination programs deliver substantial returns on public investment through cost savings within healthcare systems and broader socio-economic benefits. Preventing disease reduces the number of doctor and hospital visits, meaning valuable resources can be diverted elsewhere, and ensuring a healthy and active workforce throughout life can increase economic productivity.

The data also show that immunization of adults can produce socioeconomic returns commensurate with those of childhood immunization programs (2). Despite this, access to vaccination for adults is inconsistent around the world, with limited uptake in routine immunization schedules.

Professor Lotte Steuten, Deputy CEO of OHE and co-author of the report, says:

“Increasing pressure on ailing healthcare systems, such as an aging population, creates an urgent need to shift to a prevention-first mindset. Our report presents a compelling argument for adult immunization programs playing a key role in the shift to prevention.

Our findings show that costs are several times offset by benefits to society when governments invest in adult vaccination programs. These returns are realized through benefits for individuals, families and communities, providing a clear call to action for countries that are not yet implementing or expanding robust vaccination schedules.”

The researchers used an established framework for vaccine value to gather evidence, but found a lack of data on many elements. This finding, coupled with a lack of agreed methods to capture certain elements, means that the positive returns shown are likely an underestimate of the full value that adult vaccines bring to society.

The report has been released ahead of WHO’s World Immunization Week, and addressing such evidence gaps will be critical in achieving the ambition of the 2030 Vaccination Agenda. This includes a strategic priority to ensure that ‘all people benefit from recommended immunizations throughout the lifespan‘ and explicitly outlines the need for data-driven implementation.

Laetitia Bigger, director of vaccine policy at IFPMA, added:

“This important study broadens the lens to demonstrate that adult vaccination programs deliver real benefits to healthcare systems and societies around the world.

Vaccines are one of the most effective public health measures and can also be a powerful driver for more productive economies and resilient societies.

“It is critical that these benefits are better understood if we are to ensure that people who could benefit from adult immunization programs have access to them.”

Maarten Postma, professor of pharmacoeconomics at the University of Groningen (Netherlands) and reviewer of the report’s methodology, commented:

“Assessing the value of adult immunization gives policymakers a clearer picture of the associated benefits and costs. This comprehensive report looked internationally at four adult vaccines and used a rigorous methodological framework to assess their value.”

(1) The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) is the representative of the innovative pharmaceutical industry in official relations with the United Nations.

(2) Using the value-of-a-statistical-life approach, the return on investment for 10 childhood vaccination programs was 51.0 between 2011 and 2020 and 52.2 between 2021 and 2030 (Source: https://www.healthaffairs .org/doi/10.1377/hlthaff.2020.00103).

– ENDS –

Notes for editors

About the report

The full report ‘The Socio-Economic Value of Adult Immunization Programmes’ is available at: https://www.ohe.org/publications/the-socio-economic-value-of-adult-immunization-programmes/

About OHE

With more than 60 years of expertise, the Office of Health Economics (OHE) is the world’s oldest independent health economics research organization. Every day we work to improve healthcare through groundbreaking and innovative research, analysis and education.

As a global leader and publisher in health economics, healthcare and life sciences, we work with universities, government, healthcare systems and the pharmaceutical industry to research and respond to global health challenges.

As a government-recognized independent research organization and not-for-profit, our international reputation for the quality and independence of our research is at the heart of everything we do. OHE provides independent and groundbreaking resources, research and analysis in health economics, health policy and health statistics. Our work informs decision-making on healthcare and pharmaceutical issues on a global level.

All of our work is available online for free at www.ohe.org

About IFPMA

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents more than 90 innovative pharmaceutical companies and associations around the world. Our industry’s nearly three million employees discover, develop and deliver medicines and vaccines that advance global health. Based in Geneva, IFPMA maintains official relationships with the United Nations and contributes industry expertise to help the global health community improve the lives of people around the world. For more information, visit ifpma.org.